Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $269 from $261 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
- AbbVie upgraded to Buy from Hold at HSBC
- Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05%
- Trump Weekly: White House postpones healthcare proposal after backlash
- AbbVie receives positive CDA-AMC reimbursement recommendation for SKYRIZI